Loading...
Loading...
In a report published Monday, Credit Suisse analysts upgraded
St Jude Medical, Inc.STJ from Underperform to Neutral. The analysts expect the share price gains witnessed by
Medtronic plcMDT to diminish by mid-2015, while expecting upside to CardioMEMS sales in the long-term.
"While we expect CardioMEMS sales to be in line with guidance this year we see long-term upside based on our recently published survey. Moreover we expect Atrial Fibrillation & Neuromodulation to gain momentum over the course of the year, leaving around 5% CC sales growth after adjusting for missed selling days," the analysts said.
Credit Suisse has also forecasted top-line acceleration for St Jude to close to 3.9 percent in FY15 from 2.0 percent in FY13, on the back of continued traction from FFR & OCT as well as new product launches. In fact, there could be further upside to the estimates in the longer-term if CardioMEMS witnesses stronger-than-anticipated uptake.
"We currently forecast $77M in 2015 CardioMEMS sales vs. guidance of $70M, but note that the Street's anticipation for 2016 CardioMEMs sales will be determinative for the stock in the 2H of 2015," the analysts added. However, the sales/EPS estimates for FY15 revised down due to worsening foreign exchange rates.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in